Dasatinib
Other name
-
International/Other brands
Sprycel
Groups
Approved
Structure
Prescription products
| Name | Dosage | Strength | Route | Labeller |
|---|---|---|---|---|
| prycel | Tablet | 80 mg/1 | Oral | E.R. Squibb & Sons, L.L.C. |
| Sprycel | Tablet | 70 mg/1 | Oral | Physicians Total Care, Inc. |
| Sprycel | Tablet, film coated | 140 mg | Oral | Bristol Myers Squibb Pharma Eeig |
| Sprycel | Tablet, film coated | 50 mg | Oral | Bristol Myers Squibb Pharma Eeig |
| Sprycel | Tablet, film coated | 20 mg | Oral | Bristol Myers Squibb Pharma Eeig |
| Sprycel | Tablet, film coated | 80 mg | Oral | Bristol Myers Squibb Pharma Eeig |
| Sprycel | Tablet | 80 mg | Oral | Bristol Myers Squibb |
| Sprycel | Tablet, film coated | 70 mg | Oral | Bristol Myers Squibb Pharma Eeig |
| Sprycel | Tablet | 50 mg | Oral | Bristol Myers Squibb |
| Sprycel | Tablet | 20 mg/1 | Oral | E.R. Squibb & Sons, L.L.C. |
Target
-
Description
Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.
Indications
Acute Lymphoblastic Leukaemias (ALL); Chronic Myeloid Leukemia (CML)
Other indications
-
Mechaism of action
-
Absorption
-
Metabolism
Dasatinib is extensively metabolized in humans, primarily by the cytochrome P450 enzyme 3A4
Toxicity
Acute overdose in animals was associated with cardiotoxicity.